Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)

CompletedOBSERVATIONAL
Enrollment

214

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Mycoses
Interventions
DRUG

Posaconazole

The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00726609 - Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641) | Biotech Hunter | Biotech Hunter